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Objective. To evaluate the efficacy and safety of canakinumab treatment in active hyperimmunoglobulinemia D with periodic fever syndrome (HIDS).
Methods. This was a 3-part open-label study with an initial 6-month treatment period in which patients with HIDS (n 5 9) received canakinumab subcutaneously at a dose of 300 mg (or 4 mg/kg for those weighing £40 kg) every 6 weeks (period 1 [P1]), followed by a 6-month withdrawal period (period 2 [P2]), and then a 24-month extension treatment period with canakinumab at the same dose (period 3 [P3]). The primary end point was reduction in the frequency of attacks during treatment periods as compared to the historical period (HP; defined as the period in which patients did not receive drugs other than nonsteroidal antiinflammatory drugs and/or steroids).
Results. All 9 patients completed P1 and P2, whereas only 8 patients completed P3. All patients achieved a complete response during P1, and only 2 required dose adjustments. The number of attacks per patient decreased from a median of 5 (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] during the HP to a median of 0 (range 0-2) during P1. During P2, 7 of 9 patients experienced a disease flare within a median of 110 days (range 62-196) after the last canakinumab dose. Laboratory findings were normalized by day 15 of treatment and remained at normal levels throughout the study. Analysis of blood transcriptome profiles, assessed during P1, showed up-regulated levels of interferon and myeloid-related inflammatory responses in untreated patients compared to healthy controls, and these rapidly decreased following canakinumab injection, reaching levels comparable to those of healthy controls. At least 1 adverse event (AE) was detected in all 9 patients. Most of the AEs were mild in intensity, with infections being the most frequent AE. Serious AEs were reported in 4 patients.
Conclusion. The results of this study demonstrate the efficacy and safety of canakinumab treatment to control active HIDS and to suppress inflammation-related transcriptional responses.
Hyperimmunoglobulinemia D with periodic fever syndrome (HIDS) is a recessive autoinflammatory condition caused by biallelic MVK mutations, leading to partial activity of the mevalonate kinase enzyme, which catalyzes a key step in the synthesis pathway of cholesterol and nonsterol isoprenoids (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40146/abstract) (1, 2) . Inflammatory episodes of HIDS usually begin at infancy, last for 3-7 days, and are characterized by fever (;100%), lymphadenopathies (90%), abdominal pain (88%), diarrhea (84%), aphthous ulcers (60%), and skin rash (54%). These episodes usually recur every 4-6 weeks, and are often triggered by vaccinations, minor infections, or stress (3, 4) . Variable responses to classic antiinflammatory drugs (nonsteroidal antiinflammatory drugs [NSAIDs] , colchicine, and corticosteroids) have been reported, and biologic agents are often required to treat patients with more severe disease (3, (5) (6) (7) .
Findings of previous studies have shown that dysregulation of interleukin-1b (IL-1b) production has a role in HIDS (8, 9) . Patients with HIDS have been reported to show a decreased production of certain nonsterol isoprenoids, which globally induces defects in protein prenylation (10) . These defects may lead to inactivation of RhoA, activation of the pyrin inflammasome, and overproduction of the active forms of caspase 1 and IL-1b (11, 12) . Moreover, an efficient control of HIDS has been described in patients receiving anti-IL-1 therapies (13) (14) (15) (16) (17) (18) . Based on this evidence, we proposed a pilot study to evaluate the efficacy and safety of canakinumab, a selective long-acting human anti-IL-1b monoclonal antibody, in patients with active HIDS, the results of which are reported herein.
PATIENTS AND METHODS
Study design. The study was an open-label, phase II pilot study with a single treatment arm (canakinumb) that was conducted during 2011-2014 across 3 medical centers in Spain, comprising 2 centers for pediatric patients (Hospital Universitari Politecnic La Fe and Hospital Sant Joan de D eu) and 1 for adult patients (Hospital Universitario La Paz). The study included 3 periods (as outlined in Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40146/abstract). Period 1 (P1) was a 6-month open-label treatment period in which all patients received canakinumab subcutaneously at a dose of 300 mg every 6 weeks (or 4 mg/kg every 6 weeks for those patients weighing #40 kg). Patients who experienced a flare before week 4 received an additional dose of 150 mg (or 2 mg/kg for patients weighing #40 kg) at the time of flare, and thereafter received 450 mg every 6 weeks (or 6 mg/kg every 6 weeks for patients weighing #40 kg) starting at week 6. Patients who experienced a flare between weeks 5 and 6 received a rescue medication (NSAIDs or corticosteroids [0.5 mg/kg for 3 days]) and waited up to week 6 to receive canakinumab (450 mg, or 6 mg/kg for patients weighing #40 kg).
Period 2 (P2) was a withdrawal period of up to 6 months, during which canakinumab was not administered unless the patient experienced a disease flare. At completion of the second period or at the time of relapse, whichever occurred first, patients immediately entered period 3 (P3), a 24-month extension period in which patients received the same dose of canakinumab as administered at the end of P1. Only those who completed P1 and P2 were eligible to enter P3. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Guidelines for Good Clinical Practice, and was carried out in compliance with local regulatory requirements. Independent Ethics Committees at each participating center approved the study. All patients (or legal guardians for patients age ,18 years) provided written informed consent before entering the study.
Patients. Eligible patients (male and female) fulfilled all of the following criteria: 1) age $2 years at baseline; 2) a diagnosis of HIDS established by the identification of biallelic MVK mutations; 3) presence of active HIDS (according to a physician's global assessment of disease activity score of $2, and C-reactive protein [CRP] level of .10 mg/liter) at the start of canakinumab treatment; and 4) history of $3 inflammatory episodes, with each episode lasting $4 days and limiting the normal daily activities, during the historical period (HP) (i.e., the period defined as the most recent 6 months in which patients did not receive treatment for HIDS other than symptomatic treatment with NSAIDs and/ or corticosteroids). Patients who were previously treated with anti-IL-1, anti-tumor necrosis factor (anti-TNF), or other biologic drugs were eligible for enrollment after such treatment had been discontinued for variable time periods (24 hours for anakinra, 2 weeks for etanercept, 8 weeks for adalimumab, and 12 weeks for infliximab; for any other investigational biologic agents, at least 8 weeks or 5 half-lives prior to baseline, whichever was longer).
Exclusion criteria included the following: 1) in women, pregnancy or current lactation; 2) concomitant treatment with another investigational drug during the 30 days before enrollment; 3) history of recurrent infections and/or evidence of active infections; 4) receipt of a live-virus vaccination within 3 months prior to start of the trial; 5) positive findings on the QuantiFeron assay or purified protein derivative test (with positivity defined as $5 mm induration) at baseline or within 2 months before baseline; 6) evidence of immunologic compromise, including a positive test result for HIV (as determined by enzyme-linked immunosorbent assay and Western blotting) at screening; 7) positive test results for hepatitis B or hepatitis C; and 8) history of malignancy of any organ, treated or untreated, within the preceding 5 years.
Rationale for dose. A canakinumab dose of 300 mg (or 4 mg/kg for patients weighing #40 kg) was selected as the starting dose based on the investigators' previous experience with use of off-label anakinra for the treatment of patients with HIDS (dose range 2-4 mg/kg every day). This selected dose was higher than the dose usually prescribed for patients with cryopyrin-associated periodic syndromes (100 mg every day, or 1-2 mg/kg every day for patients weighing #40 kg) and was similar to the standard dose administered in patients with systemic-onset juvenile idiopathic arthritis (JIA) (2 mg/kg every day) (19, 20) . Evidence in the literature suggests that it was reasonable to select a dose of canakinumab similar to that used in the phase III studies involving patients with systemic-onset JIA (4 mg/kg every 4 weeks) (21) . However, due to the episodic course of HIDS, the investigators chose to administer canakinumab once every 6 weeks during P1 and P3, to assess whether this scheme could both maintain disease remission and prevent future attacks in patients with HIDS. Moreover, a single escalation of the dose (to 450 mg, or 6 mg/kg for patients weighing #40 kg) prior to week 6 was incorporated into the design of the present study for patients in whom the starting dose was not sufficient to prevent the recurrence of attacks.
Objectives and assessments. The primary objective was to assess reduction in the frequency of attacks during P1 compared to the HP. The secondary objectives included the following: 1) to assess the recurrence of attacks during P1 and P3; 2) to assess changes over time in the attack severity score as defined by the physician's and patient's global assessments of disease activity, each based on a 5-point scale (where 0 5 absent signs/ symptoms and 1 5 minimal, 2 5 mild, 3 5 moderate, and 4 5 severe disease activity); 3) to assess changes in the activity of 4 key HIDS features (fever, lymphadenopathies, aphthous ulcers, and abdominal pain) based on a 5-point scale of increasing severity (where 0 5 absent, 1 5 minimal, 2 5 mild, 3 5 moderate, and 4 5 severe); 4) to assess the extent of control of HIDS as assessed by physicians and patients at each visit of the study in P1 and P2, and every 12 weeks during P3, based on a 5-point scale (where 0 5 no control of HIDS-associated signs and symptoms since the last visit, 1 5 poor control, 2 5 some control, 3 5 good control, and 4 5 excellent control); 5) to assess changes in the CRP level over time; 6) to assess the time to resolution of attack after the first canakinumab injection, and time to relapse after the last dose in P1; 7) to assess whether a canakinumab dose adjustment and/or rescue medication was required; 8) to assess the safety of the canakinumab treatment during the study; 9) to assess the immunogenicity of the canakinumab treatment; and 10) to assess changes in gene expression profiles at different time points compared to baseline.
Criteria for attack and response to treatment. An attack was defined as a physician's global assessment of disease activity score of $2 and a CRP value of .10 mg/liter. A complete response was defined as a physician's global assessment of disease activity score of 0 or 1 and a plasma CRP level of ,10 mg/liter.
RNA sampling, extraction, and processing for microarray analysis. Total RNA was extracted and amplified as previously described (22) . Amplified RNA was hybridized to Illumina HT-12 V4 beadchips and scanned on an Illumina Beadstation 500. Data processing was completed using GenomeStudio version 2011.1 with the Gene Expression Module version 1.9.0 (Illumina). After background subtraction, the average normalization was conducted using GenomeStudio to rescale the difference in the overall intensity of gene expression to the median intensity for all samples across multiple chips. Fifteen age-and sex-matched healthy subjects were included as healthy controls to analyze changes in gene expression.
Interferome database.
Interferome is an open access database that catalogs type I, type II, and type III interferon (IFN)-stimulated genes (ISGs). Lists of differentially expressed genes revealed by the mixed-model analysis were imported into the Interferome (details available at http://www.interferome.org/) to identify ISG types at baseline and upon canakinumab treatment in patients with HIDS.
Statistical analysis. Data analyses. As this was a pilot study, no sample size calculation was performed. The full analysis set included all patients who received the study drug at least once after the baseline assessment. In general, categorical data were summarized using frequencies and percentages, whereas continuous data were reported using the number of patients and the median with interquartile range (IQR). Differences among data were established using Wilcoxon's signed rank test with continuity correction, at a significance level of 0.05.
Linear mixed model. A linear mixed model was developed to identify the transcripts that were correlated with disease and treatment. To exploit repeated measurements in the data set, spatial power structures were chosen to adjust for patient-specific covariance. Age was included as a fixed effect. Contrasts were used to test for specific comparisons of interest. The model was developed in SAS, using the MIXED procedure, and was run in JMP Genomics version 7.0 (SAS Institute).
Q-Gen analysis. Q-Gen is a QuSAGE-based approach to gene-set analysis but is more adapted for handling the results of mixed-model analysis, in that necessary adjustments to the estimates are conducted (23) . Modules with at least 15 transcripts were considered for Q-Gen analysis. Significantly enriched gene sets (blood modules) were selected based on 2 criteria: 1) a demonstrated false discovery rate P value of ,0.05, and 2) a fold change in expression of $2 or #0.5 in the comparisons considered.
Online data access. The data set described in the present study is deposited in the NCBI Gene Expression Omnibus (under GEO series accession no. GSE97075).
RESULTS
Characteristics of the patients. Ten patients with HIDS were screened, of whom 9 (6 pediatric patients and 3 adult patients) were enrolled. One pediatric patient did not fulfill the inclusion criteria (absence of active disease) and was therefore not considered eligible. The characteristics of the eligible patients are listed in Supplementary  Table 1 , and familial pedigrees with the MVK genotypes are displayed in Supplementary Figure 3 (available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40146/abstract). All 9 patients completed P1 and P2 of the trial. During P3, 1 patient (patient 6) discontinued the study due to lack of compliance with study procedures.
Efficacy. Treatment period (P1). The number of attacks per patient decreased significantly (P 5 0.009) during P1 (median number of attacks 0, range 0-2) compared to the HP (median number of attacks 5, range 3-12) (Figure 1A) . During the HP, the number of attacks observed in all patients was 59 (range 3-12), whereas in P1, only 3 attacks were reported ( Figure 1B ). All 9 patients achieved a complete response with the first canakinumab injection, with a median time to resolution of 3.0 days (range 1-5).
Seven patients received the standard dose throughout P1, with no relapse. The mean dose of canakinumab, adjusted per weight, was 5.50 mg/kg (details in Supplementary Table 1 , http://onlinelibrary.wiley.com/doi/10.1002/art. 40146/abstract). Two of 3 patients who received 4 mg/kg of canakinumab experienced attacks during P1 ( Figure 1C ) (mean duration of attacks 3.0 days, range 2-4 days). One patient (patient 4) who had an attack between weeks 5 and 6 initially received rescue medication, and at week 6, this patient was administered canakinumab at a dose of 450 mg in accordance with the protocol. The other patient (patient 2) had 2 attacks: 1 occurred at week 6 (no rescue medication was administered and the canakinumab dose was increased up to 6 mg/kg) and the second attack occurred 39 days later. After these adjustments, no additional relapses were observed in these patients during P1.
Withdrawal period (P2). All patients entered and completed P2. Only 2 patients (22.2%) did not experience an attack in P2, and these patients entered P3 after completing the 6-month drug withdrawal. The remaining 7 patients (77.8%) experienced an attack during P2, with a median time to relapse after the last canakinumab injection being 110 days (range 62-196 days) ( Figure 1D ).
Extension treatment period (P3). Eight of 9 patients completed P3. The number of attacks per patient was significantly reduced (P 5 0.008) during P3 (median number of attacks 0, range 0-4) compared to that during the HP, with a total of 8 attacks detected in P3 (Figures 1A-C) . Six of 8 attacks occurred during the first 12 months of P3, with only 2 attacks during the last 12 months of P3. During P3, none of the patients received rescue medication.
The median duration of the attacks was 3.0 days (range 2-4) during P1, 4.0 days (range 2-10) during P2, 3.5 days (range 2-8) during P3, and 8.5 days (range 6-11) for the first 12 months of P3 and last 12 months of P3. The severity of the attacks, as determined by physician's global assessment of disease activity, was mostly mild to moderate at baseline (5 mild and 4 moderate). Of the attacks that occurred in 2 patients in P1, 1 was mild and 1 was moderate, while in P2, of the attacks observed in 7 patients, 4 were mild and 3 were moderate, and in P3, of the 8 attacks that occurred in 4 patients, 5 were mild, 2 involved minimal signs/symptoms, and 1 was without signs/symptoms.
Assessment of global disease activity. At baseline, with the use of the physician's global assessment of disease activity, 6 patients were rated as having no disease control and 3 were rated as having poor disease control ( Figure  2) . By day 4 after receiving the initial dose of canakinumab, all patients were rated as having good or excellent control of the disease. These results were maintained until the end of the study, with one exception at the end of P2 (Figure 2) .
With regard to scores on the patient's assessment of disease activity, similar results were obtained, and ratings of excellent or good disease control were assessed by the patients from day 4 onward. However, at baseline, patients perceived themselves to have better control of their disease than did their physicians, considering that only 3 patients rated themselves as having no disease control and only 4 patients provided a rating of poor disease control (see Supplementary Figure 4 Severity assessment of the key signs and symptoms. At baseline, the severity of each of the key HIDS features (fever, lymphadenopathies, abdominal pain, and aphthous ulcers) was rated on a 5-point scale. Fever was rated to be moderate to severe in 88.9% of patients, whereas lymphadenopathies, abdominal pain, and aphthous ulcers were rated mild to moderate in 88.9%, 55.5%, and 44.4% of the patients, respectively. From day 4 until the end of the study, most of the patients had no or minimal HIDS features, except for mild fever in 2 patients, mild lymphadenopathies in 1 patient, mild aphthous ulcers in 1 patient, and moderate abdominal pain in 1 patient. Moreover, the severity of these signs/symptoms decreased during month 1 and months 4-6 of P1 (corresponding to those periods when the canakinumab dose was appropriately adjusted in each patient) and during P2. This improvement was sustained during P3 (results in Supplementary Figures 5 and 6 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40146/abstract). In accordance with the ratings on the physician's global assessment of disease activity, the severity of the 4 HIDS features was increased during the attack at the end of P2.
Changes in laboratory markers. At baseline, the median CRP level was elevated (median 117.7 mg/liter, range 23-165 mg/liter; normal value ,10 mg/liter). The CRP levels decreased rapidly upon canakinumab treatment, and thereafter they reached normal values by day 15 (median 0.8 mg/liter, range 0-6.0 mg/liter) and were maintained throughout the study, with only transient elevations detected during acute attacks (Figure 3 ). While most hematologic parameters remained within normal range, canakinumab treatment was associated with a decrease in the leukocyte and neutrophil counts and a mild increase in the hemoglobin level during all P1 visits compared to baseline. During the last visits of P2, a slight increase in the leukocyte and neutrophil counts was detected, both of which returned to lower values during all P3 visits (see Supplementary Figure 7 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40146/abstract).
Changes in gene expression profiles. To characterize the systemic molecular signatures of HIDS and determine how these signatures were affected by canakinumab treatment, longitudinal profiling of the blood transcriptome of HIDS patients was conducted during the period of anakinra treatment (designated visit 1 [V1]), during active disease after anakinra withdrawal (designated baseline), during 3 subsequent visits while canakinumab was being administered (designated visits 3-5 [V3-V5]), and during active disease after canakinumab withdrawal (designated visit 6 [V6]). Transcriptional profiling revealed that the samples from the anakinra treatment period and the canakinumab treatment periods clustered together and were distinct from those during the baseline treatment withdrawal period, as revealed by principal components analysis (PCA) ( Figure 4A ). When patients experienced an attack after canakinumab withdrawal (at V6), the signatures shifted closer to those at baseline.
Principal variance components analysis, which assesses the contribution of specific variables to the global variance, showed that the transcriptional variance observed was first driven by disease (weighted average proportion 26.2% in HIDS patients versus healthy controls), followed by canakinumab treatment (weighted average proportion 17.4%), and then anakinra treatment (weighted average proportion 14.6%) (results in Supplementary Figure 8 A linear mixed model accounting for repeated measurements and individual subjects was also developed. The 10,210 probes differentially expressed across comparisons were hierarchically clustered. Consistent with the PCA results, differential gene expression in the baseline group and in the attack group (at V6) clustered together, while that in the canakinumab treatment groups (at V3-V5) and anakinra treatment group (at V1) clustered together ( Figure 4B) .
Q-Gen analysis, a gene-set enrichment analysis that integrates mixed-model statistics into QuSAGE (23, 24) , was applied. Analysis of gene sets in the baseline patient group compared to the healthy control group yielded 409 transcripts that were statistically significantly up-regulated and 343 transcripts that were down-regulated in patients with HIDS (see Supplementary Tables 2 and 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40146/abstract). Inflammasomerelated genes, such as CASP1 and NLRC4, and CARD17, an IFNg-induced transcript that negatively regulates IL-1b secretion, were among the most up-regulated transcripts. At baseline, patients also displayed prominent enrichment of IL-1b and IL-1 family members (IL36, IL1R2, IL1RAP, and IL1RN) and proinflammatory receptors (IL17RA, IL18R1, IL6R, and IL10RB) (see Supplementary Table 2) . Additionally, many IFN-induced transcripts were found to be up-regulated at baseline, and then down-regulated by IL-1 blockade (at V1 and V3-V5). Comparison with the Interferome database showed that both type I and type II IFNinducible genes were included in this enriched set (see results in Supplementary Figure 9 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40146/abstract). Different antiinflammatory receptors (IL10RA, IL27RA, and IL2RB) were among the down-regulated transcripts. In patients at baseline, the transcription of the effector cytokine IL15 was up-regulated, while adaptive immunity-related cytokine transcripts and/ or receptor-encoding transcripts, such as IL16, IL21R, and IL7R, were down-regulated. Moreover, transcription of 2 proinflammatory cytokines, IL32 and IL8, was downregulated in patients during active disease (at baseline and V6) (see Supplementary Tables 2 and 3 , http://onlinelibrary. wiley.com/doi/10.1002/art.40146/abstract).
Treatment with canakinumab significantly and coordinately corrected all of these transcriptional alterations, including those induced by IFN, in a sustained and more consistent manner than that observed with anakinra (see Supplementary Tables 4 and 5 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40146/abstract). A direct comparison of drug effects on the baseline signatures of patients with HIDS showed a stronger down-regulation of 60 transcripts (.1.5-fold decrease) by canakinumab when compared to anakinra (see Supplementary Table 6 , http://onlinelibrary. wiley.com/doi/10.1002/art.40146/abstract).
Data were further interpreted using a previously described framework of 260 coexpression modules as gene sets, which were specifically designed for whole-blood transcriptome analysis and functionally annotated using knowledge-and data-driven approaches (25, 26) . The module fingerprint of HIDS at baseline, as compared to that in healthy control subjects, confirmed an up-regulation of the IFN response (M1.2, M3.4), up-regulation of myeloid lineage cells (M3.2, M7.35) and myeloid-related inflammation (M4.2, M6.13), and down-regulation of the T cell module (M4.1) and B cell module (M4.10) ( Figure 4D ). Consistent with the results of gene-level analysis, the increased expression of the IFN response and inflammation modules (sustained during active disease) was suppressed by both anti-IL-1 treatments, with the effects of canakinumab on the blood transcriptome being longlasting and quantitatively larger than those induced by anakinra treatment, an effect that was reversible upon occurrence of a flare in patients ( Figure 4D) .
Safety. All patients experienced at least 1 adverse event (AE) throughout the study. Only 1 AE (a nonserious fungal vaginitis) was suspected by the investigator to be related to the study drug. The total number of AEs was 98, of which 84 were rated as nonserious and 14 as serious (see results in Supplementary Table 7 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40146/abstract). Among the nonserious AEs, the most frequent were those of suspected infectious etiology (43.9%) that often required treatment with systemic antibiotics, of which the most frequently utilized was amoxicillin (in 4 patients) and amoxicillin in combination with b-lactamase inhibitor (in 3 patients). In only 2 patients with nonserious AEs, microbiologic studies yielded positive results (demonstrating a mycotic infection in 1 patient, and a bacteremia due to Streptococcus pneumoniae in the other patient). The treating physician in each case rated all nonserious AEs as mild in intensity, with only 1 exception (cellulitis, rated as moderate).
In total, 14 serious AEs (SAEs) were reported in 4 patients, of which 6 were mild in intensity, 5 were moderate, and 3 were severe. Eight of the 14 SAEs occurred in the same patient, who experienced acute peritonitis, anemia, bacteremia due to S pneumoniae, gastrointestinal bleeding, hypertensive crisis, pneumonia, severe anemia, and volume overload; this patient had a complicated medical history of systemic amyloid A amyloidosis, kidney transplantation, digestive hemorrhage, hypertension, and chronic anemia, and required peritoneal dialysis (see Supplementary Text, available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40146/abstract). One patient experienced hidradenitis suppurativa requiring hospitalization, and another developed cellulitis in the left arm. No deaths were reported during the study, and no patient required drug discontinuation due to AEs.
No relevant changes in clinical laboratory parameters and vital signs were observed. Among the biochemistry parameters, increased plasma levels of cholesterol, triglycerides, aspartate transaminase, alanine transaminase, and gamma glutamyl transferase were detected; in all except 1 patient, these changes were mild and transient. The patient with more severe changes had high abnormal values of alanine transferase, gamma glutamyl transferase, creatinine, and triglycerides; this patient had a medical history of systemic amyloidosis and kidney transplantation, and required peritoneal dialysis (see Supplementary Table  8 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40146/abstract). Immunogenicity was assessed using a bridging electrochemiluminescence assay, which revealed that none of the patients had developed anticanakinumab antibodies over the course of the study.
DISCUSSION
In this study, canakinumab treatment substantially reduced the frequency of attacks in patients with active HIDS, and provided a rapid and sustained control of the signs and symptoms of HIDS and a normalization of inflammation markers. The single-arm study design with 2 well-defined periods of treatment and 1 period of drug withdrawal was selected for 2 reasons. First, the small number of potentially enrolled patients would prevent clear conclusions if a double-blind, randomized, placebocontrolled withdrawal period was included in the study design. Second, this design has been used previously in studies of some rare and severe diseases (27, 28) , for which a long placebo-controlled period would be unethical because of the clear benefits from treatment.
A complete response to canakinumab was achieved rapidly in all patients, as has also been observed in patients with other monogenic autoinflammatory diseases treated with canakinumab (29) (30) (31) (32) . The clinical benefits were visible within the first week, and a significant normalization of inflammation markers was observed during the first month of treatment. During the drug withdrawal period, the time to relapse varied markedly (range 62 days to ,6 months), which suggests that the initial canakinumab dosing scheme could be modified depending on individual characteristics. These modifications may include increasing the dose of canakinumab, reducing the time between drug administration, or both. Randomized controlled trials will be required to provide further data about the optimal therapeutic scheme and administration intervals of canakinumab in patients with HIDS. This is being addressed in an ongoing, double-blind, placebo-controlled trial (the CLUSTER trial; ClinicalTrials.gov identifier NCT02059291) that is examining an every-4-weeks dosing schedule in patients with HIDS. The physician's and patient's assessments of disease control before and after drug administration changed from no or poor control at baseline to ratings of good or excellent control during treatment. The clinical benefits of the treatment were also associated with an improvement in the severity of the 4 main HIDS symptoms based on physicians' assessments. Furthermore, marked differences in the severity of each HIDS feature were detected during visit 2 and at the end of P2, probably reflecting the effect of the previously administered canakinumab treatment.
Analysis of the gene expression profiles of patients showed exuberant immune-related signatures during active disease that, for the most part, reverted upon administration of IL-1 blockade (during treatment with anakinra, at 2 time points of untreated active disease, and on consecutive visits during treatment with canakinumab). Most strikingly, both inflammasome/IL-1-related and IFNinducible gene signatures were prominent in untreated patients with active HIDS. These signatures were significantly and more consistently down-regulated by canakinumab than by anakinra. Coordinated up-regulation of these 2 signatures is not observed in patients with other autoinflammatory diseases, in whom, instead, negative crossregulation of these 2 pathways seems to take place, which is also supported in experimental models (33) (34) (35) .
In mice, protein geranylgeranylation has recently been shown to differentially regulate cytokine transcription. Macrophages that are deficient in the b-subunit of geranylgeranyl transferase 1, encoded by Pggt1b, are hyperactivated by ligation of Toll-like receptor 2 (TLR-2), TLR-4, TLR-7, and TLR-9, leading to potent up-regulation of proinflammatory cytokines, such as IL-1b, TNF, IL-6, and IL-12, which would fit with the results in our patients. However, production of both antiinflammatory IL-10 and type I IFNs was suppressed in Pggt1b-deficient mouse macrophages (36) . The coordinated expression of IL-1-related and IFN-inducible gene transcripts in HIDS patients and the reversal of this up-regulated gene expression upon IL-1 blockade thus support the notion that the regulation of these pathways in humans follows a pattern distinct from that seen in MVK-deficient mice.
No new or unexpected safety issues were observed during the study. The safety profile was consistent with that observed in other canakinumab studies (29) (30) (31) (32) . Only 4 patients reported experiencing SAEs, with 66.6% of the SAEs occurring in a single patient who showed a severe form of HIDS with AA amyloidosis. The fact that most of the SAEs reported in this patient were detected previously, before enrollment, made it difficult to establish a clear causal relationship to the study drug. Furthermore, the beneficial effect of canakinumab in this patient was evident, as has been previously shown. As expected, infections were the most frequently detected AEs in the study. This phenomenon has been described in patients treated with other anti-IL-1 drugs, independent of its molecular structure, and probably reflects an interference of IL-1 blockade in different antimicrobial immune responses (29) (30) (31) (32) (37) (38) (39) (40) (41) (42) . Thus, monitoring for complications related to infections is required in patients receiving canakinumab treatment.
Despite sample size limitations, this open-label, phase II pilot study showed, for the first time, that canakinumab administered every 6 weeks markedly reduced the rate of acute attacks and sustained a good/excellent disease control with a well-tolerated safety profile. The interindividual heterogeneity observed during the study concerning the appropriate canakinumab dose and the time to relapse after the last drug injection suggests that potential modifications to the initial dosing scheme could be considered. Further studies involving a large number of patients with HIDS are warranted to delineate the optimal therapeutic scheme and assess its efficacy and safety over the long term.
